The influence of severe mitral regurgitation on major adverse cardiac and cerebrovascular events after myocardial infarction in 1-year follow-up: Data from PL-ACS registry.

mitral regurgitation mortality myocardial infarction

Journal

Kardiologia polska
ISSN: 1897-4279
Titre abrégé: Kardiol Pol
Pays: Poland
ID NLM: 0376352

Informations de publication

Date de publication:
16 Mar 2023
Historique:
received: 03 03 2023
accepted: 03 03 2023
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 18 3 2023
Statut: aheadofprint

Résumé

Mitral regurgitation (MR) is frequently observed in patients with myocardial infarction (MI). However, the incidence of severe MR in contemporary population is unknown. The study evaluates the prevalence and prognostic impact of severe MR in contemporary population of patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). The study group consists of 8062 patients enrolled in the Polish Registry of Acute Coronary Syndromes over the years 2017‒2019. Only the patients with full echocardiography performed during the index hospitalization were eligible. Primary composite outcome was 12-month major adverse cardiac and cerebrovascular events (MACCE) (death, non-fatal MI, stroke and heart failure [HF] hospitalization) compared between patients with and without severe MR. 5561 NSTEMI patients and 2501 STEMI patients were enrolled into the study. Severe MR occurred in 66 (1.19%) NSTEMI patients and 30 (1.19%) STEMI patients. Multivariable regression models revealed that severe MR is an independent risk factor of all-cause death in 12-month observation (odds ratio [OR], 1.839; 95% confidence interval [CI], 1.012‒3.343; P = 0.046) in all MI patients. Patients with NSTEMI and severe MR had higher mortality (22.7% vs. 7.1%), HF rehospitalization rate (39.4% vs. 12.9%) and MACCE occurrence (54.5% vs. 29.3%). Severe MR was associated with higher mortality (20% vs. 6%) and higher HF rehospitalization (30% vs. 9.8%), stroke (10% vs. 0.8%) and MACCE rates (50% vs. 23.1%) in STEMI patients. Severe MR is associated with higher mortality and MACCE occurrence in patients with MI in 12-month follow-up. Severe MR is an independent risk factor of all-cause death.

Sections du résumé

BACKGROUND BACKGROUND
Mitral regurgitation (MR) is frequently observed in patients with myocardial infarction (MI). However, the incidence of severe MR in contemporary population is unknown.
AIMS OBJECTIVE
The study evaluates the prevalence and prognostic impact of severe MR in contemporary population of patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI).
METHODS METHODS
The study group consists of 8062 patients enrolled in the Polish Registry of Acute Coronary Syndromes over the years 2017‒2019. Only the patients with full echocardiography performed during the index hospitalization were eligible. Primary composite outcome was 12-month major adverse cardiac and cerebrovascular events (MACCE) (death, non-fatal MI, stroke and heart failure [HF] hospitalization) compared between patients with and without severe MR.
RESULTS RESULTS
5561 NSTEMI patients and 2501 STEMI patients were enrolled into the study. Severe MR occurred in 66 (1.19%) NSTEMI patients and 30 (1.19%) STEMI patients. Multivariable regression models revealed that severe MR is an independent risk factor of all-cause death in 12-month observation (odds ratio [OR], 1.839; 95% confidence interval [CI], 1.012‒3.343; P = 0.046) in all MI patients. Patients with NSTEMI and severe MR had higher mortality (22.7% vs. 7.1%), HF rehospitalization rate (39.4% vs. 12.9%) and MACCE occurrence (54.5% vs. 29.3%). Severe MR was associated with higher mortality (20% vs. 6%) and higher HF rehospitalization (30% vs. 9.8%), stroke (10% vs. 0.8%) and MACCE rates (50% vs. 23.1%) in STEMI patients.
CONCLUSIONS CONCLUSIONS
Severe MR is associated with higher mortality and MACCE occurrence in patients with MI in 12-month follow-up. Severe MR is an independent risk factor of all-cause death.

Identifiants

pubmed: 36929297
pii: VM/OJS/J/94495
doi: 10.33963/KP.a2023.0064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Szymon Ładziński (S)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. szymon.ladzinski@gmail.com.

Jacek Niedziela (J)

3rd Department of Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Katowice, Poland.

Adam Witkowski (A)

Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warszawa, Poland.

Stanisław Bartuś (S)

2nd Department of Cardiology, Medical College, Jagiellonian University, Kraków, Poland.

Maciej Lesiak (M)

Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland.

Krzysztof Milewski (K)

Research and Development Center, American Heart of Poland, Warszawa, Poland.

Marek Gierlotka (M)

Department of Cardiology, Faculty of Medicine, University of Opole, Opole, Poland.

Przemysław Trzeciak (P)

3rd Department of Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Katowice, Poland.

Mariusz Gąsior (M)

3rd Department of Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Katowice, Poland.

Wojciech Wojakowski (W)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Classifications MeSH